All In Biotech

Drug Trial Radar · NCT06617429

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects With Angelman Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

129

Actual

Start

Dec 3, 2024

Primary completion

Jul 10, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

Conditions

  • Angelman Syndrome

Interventions

  • GTX-102Drug

    antisense oligonucleotide

  • Sham-LPProcedure

    Small needle prick on the lower back at the location where the LP injection is normally made

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Bayley-4 Cognitive Raw Score Without Caregiver Input at Day 338Time frame: Baseline, Day 338

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Cedars Sinai

    Los Angeles, California

  • UCSD, Rady Children's Hospital

    San Diego, California

  • UCSF

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nicklaus Children's Hospital

    Miami, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Rush University

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Mercy

    Kansas City, Missouri

  • Columbia University Medical Center

    New York, New York

  • UNC Chapel Hill Pediatrics

    Chapel Hill, North Carolina

  • Rare Disease Research

    Hillsborough, North Carolina

  • The University of Texas

    Austin, Texas

  • Carum Research Inc

    Dallas, Texas

  • British Columbia Children's Hospital

    Vancouver, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • University of Leipzig

    Leipzig, Germany

  • Haunersche Kinderklinik

    Munich, Germany

  • Osaka City General Hospital

    Osaka, Japan

  • Hokkaido University Hospital

    Sapporo, Japan

  • Nagoya City University Graduate School of Medical Sciences

    Nagoya, Aichi-ken, Japan

  • Medical University of Gdańsk

    Gdansk, Poland

  • Polish Mothers Memorial Institute

    Lodz, Poland

  • Hospital Universitario Parc Tauli

    Barcelona, Spain

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.